GleamWall
中文EN

MIST Milestone Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1408443 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-68.7%
TTM EPS YoY6.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,370.6%
ROA-78.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets103.8%
Debt / equity—
Current ratio6.27x
Interest coverage-7.62x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.96M$559,000$238,000—$0$0$0—
Cost of revenue$325,000$32,000$14,000—$0$0$0—
Gross profit$2.64M$527,000$224,000—$0$0$0—
R&D expense$3.46M$3.51M$3.25M$5.52M$3.94M$3.67M$4.98M$3.94M
SG&A expense$24.23M$22.65M$4.82M$5.08M$7.89M$8.86M$5.17M$4.00M
Operating income-$25.05M-$25.63M-$23.66M-$17.26M-$11.83M-$12.53M-$20.52M-$12.35M
Interest expense$2.18M$4.72M$4.13M$985,000$967,000$951,000$935,000$919,000
Net income-$25.80M-$28.61M-$26.07M-$17.41M-$11.92M-$12.97M-$20.76M-$12.36M
EBITDA-$25.00M-$25.57M-$23.61M-$17.22M-$11.80M-$12.50M-$20.50M-$12.32M
EPS (basic)-0.18-0.21-0.20—-0.12-0.20-0.31—
EPS (diluted)-0.18-0.21-0.20—-0.12-0.20-0.31—
Balance sheet
Cash & equivalents$144.47M$169.73M$71.32M$73.05M$46.69M$42.50M$45.09M$25.31M
Short-term investments$882,000$881,000$112.90M$32.91M$35.90M$918,000$10.87M$44.38M
Receivables$3.93M$2.72M$1.60M—————
Inventory$6.68M$4.72M$1.83M$648,000————
Current assets$161.60M$180.33M$192.25M$111.92M$86.67M$46.17M$60.48M$73.93M
PP&E, net$416,000$469,000$500,000$511,000$136,000$159,000$176,000$197,000
Total assets$162.69M$181.62M$193.73M$113.56M$87.75M$47.42M$61.88M$75.50M
Current liabilities$25.78M$22.18M$20.94M$13.98M$10.52M$9.28M$12.96M$8.13M
Long-term debt$60.24M$59.21M$58.19M$57.19M$56.21M$55.24M$54.29M$53.35M
Total debt$60.24M$59.21M$58.19M$57.19M$56.21M$55.24M$54.29M$53.35M
Total liabilities$168.91M$163.41M$157.69M$71.79M$67.25M$65.16M$68.01M$62.35M
Shareholders' equity-$6.22M$18.22M$36.05M$41.77M$20.50M-$17.75M-$6.12M$13.15M
Net debt-$84.23M-$110.52M-$13.12M-$15.86M$9.52M$12.74M$9.20M$28.04M
Shares outstanding124.50M124.50M117.79M106.24M85.17M53.49M53.46M53.35M
Cash flow statement
Operating cash flow-$25.24M-$22.71M-$16.05M-$12.78M-$9.75M-$12.57M-$13.95M-$6.84M
Capital expenditure$4,000$26,000$45,000$283,000$2,000$11,000$6,000$22,000
Free cash flow-$25.25M-$22.74M-$16.10M-$13.06M-$9.75M-$12.58M-$13.96M-$6.87M
Investing cash flow-$5,000$111.99M-$80.03M$2.70M-$34.98M$9.94M$33.58M$19.33M
Financing cash flow-$9,000$9.13M$94.35M$36.43M$48.92M$36,000$140,000$24,000
Depreciation & amortization$57,000$57,000$56,000$34,000$25,000$28,000$27,000$26,000
Stock-based compensation$1.36M$1.34M$1.28M$3.55M$1.25M$1.31M$1.35M$1.47M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.